Traveler’s Diarrhea - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Traveler's Diarrhea - Pipeline Review, H2 2016’, provides an overview of the Traveler's Diarrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Traveler's Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traveler's Diarrhea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Traveler's Diarrhea

The report reviews pipeline therapeutics for Traveler's Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Traveler's Diarrhea therapeutics and enlists all their major and minor projects

The report assesses Traveler's Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Traveler's Diarrhea

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Traveler's Diarrhea

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Traveler's Diarrhea pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Cosmo Pharmaceuticals NV

GlaxoSmithKline Plc

Nippon Shinyaku Co., Ltd.

Prokarium Limited

Scandinavian Biopharma Holding AB

Sigmoid Pharma Limited

Cosmo Pharmaceuticals NV

GlaxoSmithKline Plc

Nippon Shinyaku Co., Ltd.

Prokarium Limited

Scandinavian Biopharma Holding AB

Sigmoid Pharma Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Traveler's Diarrhea ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Traveler's Diarrhea Overview 7

Therapeutics Development 8

Pipeline Products for Traveler's Diarrhea - Overview 8

Pipeline Products for Traveler's Diarrhea - Comparative Analysis 9

Traveler's Diarrhea - Therapeutics under Development by Companies 10

Traveler's Diarrhea - Therapeutics under Investigation by Universities/Institutes 11

Traveler's Diarrhea - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Traveler's Diarrhea - Products under Development by Companies 15

Traveler's Diarrhea - Products under Investigation by Universities/Institutes 16

Traveler's Diarrhea - Companies Involved in Therapeutics Development 17

Cosmo Pharmaceuticals NV 17

GlaxoSmithKline Plc 18

Nippon Shinyaku Co., Ltd. 19

Prokarium Limited 20

Scandinavian Biopharma Holding AB 21

Sigmoid Pharma Limited 22

Traveler's Diarrhea - Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

Etvax - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

GVXNSD-133 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

IMSUTMR-1501 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

prulifloxacin - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

rifamycin CR - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Typhetec - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Vaccine for Traveler's Diarrhea - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Vaccine for Traveler's Diarrhea - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Traveler's Diarrhea - Dormant Projects 44

Traveler's Diarrhea - Discontinued Products 45

Traveler's Diarrhea - Product Development Milestones 46

Featured News & Press Releases 46

Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX 46

Oct 04, 2013: Santarus Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers’ Diarrhea 46

Sep 11, 2012: Santarus Announces Positive Top-Line Phase III Results For Rifamycin SV MMX In Travelers' Diarrhea 47

Sep 14, 2009: Data From Optimers Second Phase III Study of Prulifloxacin Presented At Annual Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC) 48

Sep 02, 2009: Optimer Pharmaceuticals Announces Presentations Of Additional Phase III Prulifloxacin Data At Upcoming ICAAC Annual Meeting 49

Feb 26, 2009: Optimer Pharmaceuticals Announces Publication In Peer-Reviewed Journal About Prulifloxacins Antibacterial Activity Against Infectious Diarrhea Producing Bacteria 49

Feb 24, 2009: Optimer Pharmaceuticals Announces Positive Results From Second Phase III Study Of Prulifloxacin For Infectious Diarrhea In Travelers 50

Oct 20, 2008: Data from Optimer Pharmaceuticals Prulifloxacin Phase III Trial In Travelers Diarrhea Presented At ICAAC/IDSA Annual Meeting 51

Sep 02, 2008: Optimer Pharmaceuticals Completes Enrollment In Second Prulifloxacin Phase III Clinical Trial 51

Jul 16, 2008: Optimer Pharmaceuticals Announces Positive Results In Prulifloxacin Phase III Study 52

Mar 11, 2008: Optimer Pharmaceuticals Completes Enrollment In Phase III Clinical Trial Of Prulifloxacin In Patients with Travelers’ Diarrhea 52

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

List of Tables

Number of Products under Development for Traveler's Diarrhea, H2 2016 8

Number of Products under Development for Traveler's Diarrhea - Comparative Analysis, H2 ...

List of Tables

Number of Products under Development for Traveler's Diarrhea, H2 2016 8

Number of Products under Development for Traveler's Diarrhea - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Traveler's Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H2 2016 17

Traveler's Diarrhea - Pipeline by GlaxoSmithKline Plc, H2 2016 18

Traveler's Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 19

Traveler's Diarrhea - Pipeline by Prokarium Limited, H2 2016 20

Traveler's Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2016 21

Traveler's Diarrhea - Pipeline by Sigmoid Pharma Limited, H2 2016 22

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Stage and Target, H2 2016 25

Number of Products by Stage and Mechanism of Action, H2 2016 27

Number of Products by Stage and Route of Administration, H2 2016 29

Number of Products by Stage and Molecule Type, H2 2016 31

Traveler's Diarrhea - Dormant Projects, H2 2016 44

Traveler's Diarrhea - Discontinued Products, H2 2016 45

List of Figures

List of Figures

Number of Products under Development for Traveler's Diarrhea, H2 2016 8

Number of Products under Development for Traveler's Diarrhea - Comparative Analysis, H2 ...

List of Figures

Number of Products under Development for Traveler's Diarrhea, H2 2016 8

Number of Products under Development for Traveler's Diarrhea - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Targets, H2 2016 24

Number of Products by Stage and Top 10 Targets, H2 2016 24

Number of Products by Mechanism of Actions, H2 2016 26

Number of Products by Stage and Mechanism of Actions, H2 2016 26

Number of Products by Routes of Administration, H2 2016 28

Number of Products by Stage and Routes of Administration, H2 2016 28

Number of Products by Molecule Types, H2 2016 30

Number of Products by Stage and Molecule Types, H2 2016 30

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports